JSPR Company Profile and Key Details

JSPR has shown mixed momentum, gaining 4.05% over the past week and -37.14% over the past quarter, though year-to-date performance is down -15.85%. Short-term trend indicators are bullishly aligned (SMA20 3.05%, SMA50 -10.59%, SMA200 -50.34%). The stock’s 14-day RSI is 48.95 (neutral), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -80.53% below its high and over 26.13% above its low. Average 10-day trading volume of 323.99 thousand shares is below the 3-month average of 1.73 million, indicating normal recent market interest.

Jasper Therapeutics, Inc. generated EPS of -$5.90 over the past year. Five-year average earnings growth is 54.53%. Wall Street analysts project EPS growth of 27.4% annually over the next five years. The latest quarter delivered EPS of -$1.13. The next quarter is forecast at -$0.71. Next year's EPS is expected at $0.45. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 5 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $65.00 to $4.00. The high target offers 4542.86% upside. The low target suggests 185.71% downside. The mean target is $19.75. This offers 1310.71% upside. Jasper Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 10, 2025, missed forecasts by 11.88%. The prior quarter beat by 45.0%. Over the last six quarters, Apple has recorded several small beats. These include -11.01% in August 13, 2024.

Jasper Therapeutics, Inc. has 16.25 million shares outstanding. The public float is 11.14 million shares, elevated short interest at 8.69% of float. This equals 1.29 million shares. The short ratio is 1.02 days. Institutional investors hold 79.24% of the float. Insiders own 1.17%. Qiming U.S. Healthcare Fund II, L.P. holds 8.52 million shares, ROCHE HOLDING LTD has 4.55 million shares and Velan Capital Investment Management LP has 1.19 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Jasper Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.79. This means the shares are trading below this model’s fair value.

Jasper Therapeutics, Inc. (NASDAQ:JSPR) closed at $1.40 USD, gaining $0.02 (1.45%) from the previous close of $1.38. The stock is currently mid-range between its 52-week high and low $1.11 and $7.19. With a market capitalization of about $22.75 million, Jasper Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.09). Key stats such as the average daily volume over the past year has been around 1.83 million shares, volume is running light vs its 52-week average. Headquartered in Redwood City, CA, Jasper Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jeetinder Singh Mahal, the company employs approximately 64 people and listed since January 10, 2020. Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.

Our AI price prediction model suggests that Jasper Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.0%, with price expected at $1.26 by March 11, 2026, within a range of $1.12 to $1.38 3-Month Outlook: Projected rise of 63.57%, reaching $2.29 by May 25, 2026, with a range of $1.83 to $2.77. 1-Year Outlook: Projected loss of -87.14%, with price at $0.18 by February 25, 2027, within a range of $0.00 to $0.00.

Jasper Therapeutics, Inc. (NASDAQ:JSPR) shares are down -15.85% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Jasper Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.26. Analyst sentiment is cautious, with the majority of ratings in Sector Perform territory and a mean price target of $32.23, suggesting 2202.14% upside. Our AI forecast model points to short-term weakness (-10.0% over two weeks), a medium-term rise (63.57% over three months), and a longer-term loss (-87.14% over one year), with expected trading ranges indicating moderate volatility.

Jasper Therapeutics, Inc. trades at a P/E ratio of -0.26, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.03 suggesting the stock is closer to book value. The P/FCF stands at -0.3, also above market averages.